View Financial HealthLavipharm 배당 및 자사주 매입배당 기준 점검 0/6Lavipharm 은(는) 현재 수익률이 1.28% 인 배당금 지급 회사입니다.핵심 정보1.3%배당 수익률0.07%자사주 매입 수익률총 주주 수익률1.4%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향172%최근 배당 및 자사주 매입 업데이트Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.모든 업데이트 보기Recent updatesNew Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026분석 기사 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).분석 기사 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024분석 기사 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024분석 기사 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023분석 기사 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.공시 • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.공시 • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.분석 기사 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 이제 막 배당금 지급을 시작했기 때문에 LAVI 의 배당금 지급이 안정적인지 여부를 판단하기에는 너무 이릅니다.배당금 증가: 이제 막 배당금 지급을 시작했기 때문에 LAVI 의 배당금 지급액이 늘어나고 있는지 판단하기에는 너무 이릅니다.배당 수익률 vs 시장Lavipharm 배당 수익률 vs 시장LAVI의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (LAVI)1.3%시장 하위 25% (GR)2.1%시장 상위 25% (GR)5.3%업계 평균 (Pharmaceuticals)2.7%분석가 예측 (LAVI) (최대 3년)n/a주목할만한 배당금: LAVI 의 배당금( 1.28% )은 Greek 시장에서 배당금 지급자의 하위 25%( 2.13% )와 비교해 주목할 만하지 않습니다.고배당: LAVI 의 배당금( 1.28% )은 Greek 시장에서 배당금 지급자의 상위 25%( 5.26% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 지급 비율 ( 172.4% )이 높기 때문에 LAVI 의 배당금 지급은 수익으로 잘 충당되지 않습니다.주주 현금 배당현금 흐름 범위: 현금 지급 비율 ( 167.1% )이 높기 때문에 LAVI 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YGR 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 07:38종가2026/06/15 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lavipharm S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.
New Risk • Jun 04New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 47% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (47% net debt to equity). Share price has been volatile over the past 3 months (6.4% average weekly change). Profit margins are more than 30% lower than last year (8.0% net profit margin).
Reported Earnings • May 29First quarter 2026 earnings released: EPS: €0.005 (vs €0.005 in 1Q 2025)First quarter 2026 results: EPS: €0.005 (in line with 1Q 2025). Revenue: €14.7m (up 9.7% from 1Q 2025). Net income: €820.0k (down 2.7% from 1Q 2025). Profit margin: 5.6% (down from 6.3% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth.
분석 기사 • May 01Earnings Troubles May Signal Larger Issues for Lavipharm (ATH:LAVI) ShareholdersLavipharm S.A.'s ( ATH:LAVI ) recent weak earnings report didn't cause a big stock movement. We think that investors...
Reported Earnings • Apr 29Full year 2025 earnings released: EPS: €0.03 (vs €0.052 in FY 2024)Full year 2025 results: EPS: €0.03 (down from €0.052 in FY 2024). Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 54% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • Apr 09Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.42, the stock trades at a trailing P/E ratio of 47.4x. Average trailing P/E is 21x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 253% over the past three years.
Reported Earnings • Mar 20Full year 2025 earnings releasedFull year 2025 results: Revenue: €62.6m (up 18% from FY 2024). Net income: €5.05m (down 42% from FY 2024). Profit margin: 8.1% (down from 16% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has increased by 44% per year, which means it is well ahead of earnings.
공시 • Mar 06+ 2 more updatesLavipharm S.A. to Report Fiscal Year 2025 Results on Apr 23, 2026Lavipharm S.A. announced that they will report fiscal year 2025 results at 5:20 PM, GTB Standard Time on Apr 23, 2026
분석 기사 • Jan 28Even With A 27% Surge, Cautious Investors Are Not Rewarding Lavipharm S.A.'s (ATH:LAVI) Performance CompletelyDespite an already strong run, Lavipharm S.A. ( ATH:LAVI ) shares have been powering on, with a gain of 27% in the last...
New Risk • Jan 26New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.7x net interest cover). Minor Risks Share price has been volatile over the past 3 months (5.3% average weekly change). Profit margins are more than 30% lower than last year (3.8% net profit margin).
분석 기사 • Dec 18Lavipharm (ATH:LAVI) Takes On Some Risk With Its Use Of DebtThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
New Risk • Nov 26New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.7x net interest cover). Dividend is not well covered by earnings and cash flows. Payout ratio: 172% Paying a dividend despite having no free cash flows. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin).
Upcoming Dividend • Jul 10Inaugural dividend of €0.02 per shareEligible shareholders must have bought the stock before 17 July 2025. Payment date: 24 July 2025. This is the first dividend for Lavipharm since going public. The average dividend yield among industry peers is 2.8%.
분석 기사 • Apr 10We Think Shareholders Should Be Aware Of Some Factors Beyond Lavipharm's (ATH:LAVI) ProfitThe latest earnings release from Lavipharm S.A. ( ATH:LAVI ) disappointed investors. We did some digging and found some...
Reported Earnings • Apr 08Full year 2024 earnings released: EPS: €0.052 (vs €0.012 in FY 2023)Full year 2024 results: EPS: €0.052 (up from €0.012 in FY 2023). Revenue: €52.9m (up 11% from FY 2023). Net income: €8.67m (up 340% from FY 2023). Profit margin: 16% (up from 4.1% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings.
New Risk • Mar 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.9x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.9x net interest cover). Minor Risk Share price has been volatile over the past 3 months (4.8% average weekly change).
공시 • Mar 15Lavipharm S.A., Annual General Meeting, Jul 03, 2025Lavipharm S.A., Annual General Meeting, Jul 03, 2025.
New Risk • Dec 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (4.4% average weekly change). Large one-off items impacting financial results.
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2024 Results on Nov 14, 2024Lavipharm S.A. announced that they will report nine months, 2024 results on Nov 14, 2024
분석 기사 • Sep 26Lavipharm's (ATH:LAVI) Earnings Aren't As Good As They AppearDespite posting strong earnings, Lavipharm S.A.'s ( ATH:LAVI ) stock didn't move much over the last week. We looked...
Reported Earnings • Sep 20Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €13.1m (down 16% from 2Q 2023). Net income: €6.63m (up 307% from 2Q 2023). Profit margin: 50% (up from 10% in 2Q 2023).
공시 • Sep 02Lavipharm S.A. to Report First Half, 2024 Results on Sep 19, 2024Lavipharm S.A. announced that they will report first half, 2024 results on Sep 19, 2024
분석 기사 • Aug 06Some Shareholders Feeling Restless Over Lavipharm S.A.'s (ATH:LAVI) P/E RatioWith a price-to-earnings (or "P/E") ratio of 61.9x Lavipharm S.A. ( ATH:LAVI ) may be sending very bearish signals at...
New Risk • May 29New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 2.3x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (2.3x net interest cover). Minor Risk Large one-off items impacting financial results.
공시 • May 01Lavipharm S.A. to Report Q1, 2024 Results on May 23, 2024Lavipharm S.A. announced that they will report Q1, 2024 results at 5:20 PM, GTB Standard Time on May 23, 2024
New Risk • Apr 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Greek stocks, typically moving 4.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Mar 05Full year 2023 earnings releasedFull year 2023 results: Revenue: €50.9m (up 11% from FY 2022). Net income: €2.00m (up 139% from FY 2022). Profit margin: 3.9% (up from 1.8% in FY 2022). The increase in margin was driven by higher revenue.
공시 • Mar 01Lavipharm S.A. to Report Fiscal Year 2023 Results on Mar 21, 2024Lavipharm S.A. announced that they will report fiscal year 2023 results on Mar 21, 2024
Reported Earnings • Nov 10Third quarter 2023 earnings released: €0.001 loss per share (vs €0.021 loss in 3Q 2022)Third quarter 2023 results: €0.001 loss per share (improved from €0.021 loss in 3Q 2022). Revenue: €11.7m (down 5.6% from 3Q 2022). Net loss: €118.0k (loss narrowed 78% from 3Q 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 51 percentage points per year, which is a significant difference in performance.
공시 • Nov 01Lavipharm S.A. to Report Nine Months, 2023 Results on Nov 08, 2023Lavipharm S.A. announced that they will report nine months, 2023 results on Nov 08, 2023
분석 기사 • Nov 01Here's Why Lavipharm (ATH:LAVI) Has A Meaningful Debt BurdenHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Reported Earnings • Sep 24Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €15.6m (up 52% from 2Q 2022). Net income: €1.63m (up 63% from 2Q 2022). Profit margin: 10% (in line with 2Q 2022).
공시 • Sep 01Lavipharm S.A. to Report First Half, 2024 Results on Sep 21, 2023Lavipharm S.A. announced that they will report first half, 2024 results on Sep 21, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non Executive Director Sophia Kounenaki-Efraimoglou was the last independent director to join the board, commencing their role in 2019. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Sep 17First half 2022 earnings released: EPS: €0.037 (vs €0.15 in 1H 2021)First half 2022 results: EPS: €0.037 (down from €0.15 in 1H 2021). Revenue: €21.2m (up 8.4% from 1H 2021). Net income: €1.90m (down 27% from 1H 2021). Profit margin: 9.0% (down from 13% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
공시 • Aug 09Lavipharm S.A., Annual General Meeting, Aug 30, 2022Lavipharm S.A., Annual General Meeting, Aug 30, 2022.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment improved over the past weekAfter last week's 19% share price gain to €1.39, the stock trades at a trailing P/E ratio of 13.7x. Average trailing P/E is 18x in the Pharmaceuticals industry in Europe. Total returns to shareholders of 64% over the past three years.
공시 • Jun 01Lavipharm S.A., Annual General Meeting, Jun 30, 2022Lavipharm S.A., Annual General Meeting, Jun 30, 2022.
Buying Opportunity • May 26Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 25%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Buying Opportunity • May 06Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 36%. The fair value is estimated to be €0.57, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.5% over the last 3 years, while earnings per share has been flat.
Board Change • Apr 27Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (4 non-independent directors). Executive Director Telemaque Lavidas is the most experienced director on the board, commencing their role in 2019. Independent Non Executive Director James Christopoulos was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Reported Earnings • Oct 03First half 2021 earnings released: EPS €0.051 (vs €0.042 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: €19.6m (up 7.1% from 1H 2020). Net income: €2.60m (up 20% from 1H 2020). Profit margin: 13% (up from 12% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 49% per year.
Reported Earnings • May 02Full year 2020 earnings released: EPS €0.042 (vs €0.10 in FY 2019)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2020 results: Revenue: €37.6m (up 12% from FY 2019). Net income: €2.17m (down 59% from FY 2019). Profit margin: 5.8% (down from 16% in FY 2019). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 46% per year, which means it is well ahead of earnings.
분석 기사 • Feb 11We're Not Counting On Lavipharm (ATH:LAVI) To Sustain Its Statutory ProfitabilityBroadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...
Is New 90 Day High Low • Nov 11New 90-day high: €0.40The company is up 38% from its price of €0.29 on 13 August 2020. The Greek market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Oct 08New 90-day high: €0.37The company is up 29% from its price of €0.29 on 10 July 2020. The Greek market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 4.0% over the same period.
Reported Earnings • Oct 01First half earnings releasedOver the last 12 months the company has reported total profits of €6.88m, up 397% from the prior year. Total revenue was €35.7m over the last 12 months, up 5.8% from the prior year.